Cancer Letters
Volume 286, Issue 1 , Pages 29-37 , 1 December 2009

The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy

Received 4 November 2008 ,Revised 26 February 2009 ,Accepted 27 February 2009.

References 

  1. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991;350:427–428
  2. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429–431
  3. McLean M, Dutton MF. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol. Ther. 1995;65:163–192
  4. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am. J. Clin. Nutr. 2004;80:1106–1122
  5. International Agency for Research on Cancer. Aflatoxins in Some Traditional Herbal Medicines Some Mycotoxins Naphtalene and Styrene. Lyon: IARCPress; 2002;
  6. Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res. 1992;52:2114s–2118s
  7. J. Ferlay, P. Bray, P. Pinasi, D.M. Parkin, GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, Lyon, 2004.
  8. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 2003;23:405–409
  9. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res. 1996;366:23–44
  10. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007;28:622–629
  11. Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H, Langouët S. Activation and detoxication of aflatoxin B1. Mutat. Res. 1998;402:121–128
  12. Johnson WW, Guengerich FP. Reaction of aflatoxin B1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. Proc. Natl. Acad. Sci. USA. 1997;94:6121–6125
  13. Iyer RS, Coles BF, Raney KD, Thier R, Guengerich FP, Harris TM. DNA adduction by the potent carcinogen aflatoxin B1: mechanistic studies. J. Am. Chem. Soc. 1994;116:1603–1609
  14. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis. 2001;22:535–545
  15. Bedard LL, Massey TE. Aflatoxin B1-induced DNA damage and its repair. Cancer Lett. 2006;241:174–183
  16. Kirk GD, Turner PC, Gong Y, Lesi OA, Mendy M, Goedert JJ, et al. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol. Biomar. Prev. 2005;14:373–379
  17. Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 1991;51:6185–6189
  18. Denissenko MF, Koudriakova TB, Smith L, O’Connor TR, Riggs AD, Pfeifer GP. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene. 1998;17:3007–3014
  19. Aguilar F, Hussain S, Cerutti P. Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA. 1993;90:8586–8590
  20. Tong WM, Lee MK, Galendo D, Wang ZQ, Sabapathy K. Aflatoxin-B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock-in) mice. Int. J.. Cancer. 2006;119:745–749
  21. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene. 2001;20:320–328
  22. Aguilar F, Harris C, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 1994;264:1317–1319
  23. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24:5858–5867
  24. Ponchel F, Puisieux A, Tabone E, Michot JP, Fröschl G, Morel AP, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res. 1994;54:2064–2068
  25. Schleger C, Becker R, Oesch F, Steinberg P. The human p53 gene mutated at position 249 per se is not sufficient to immortalize human liver cells. Hepatology. 1999;29:834–838
  26. Dumenco L, Oguey D, Wu J, Messier N, Fausto N. Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology. 1995;22:1279–1288
  27. Oguey D, Dumenco LL, Pierce RH, Fausto N. Analysis of the tumorigenicity of the X gene of hepatitis B virus in a nontransformed hepatocyte cell line and the effects of cotransfection with a murine p53 mutant equivalent to human codon 249. Hepatology. 1996;24:1024–1033
  28. Yin L, Ghebranious N, Chakraborty S, Sheehan CE, Ilic Z, Sell S. Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutation in vivo. Hepatology. 1998;27:73–80
  29. Ghebranious N, Sell S. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology. 1998;27:967–973
  30. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346–355
  31. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene. 2000;19:1245–1256
  32. Friedler A, DeDecker BS, Freund SM, Blair C, Rüdiger S, Fersht AR. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for “mutant conformation”. J. Mol. Biol. 2004;336:187–196
  33. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 2005;280:16030–16037
  34. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People’s Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol. Biomar. Prev. 2001;10:617–625
  35. Kirby GM, Chemin I, Montesano R, Chisari FV, Lang MA, Wild CP. Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol. Carcinogen. 1994;11:74–80
  36. Hussain S, Aguilar F, Amstad P, Cerutti P. Oxy-radical induced mutagenesis of hotspot codons 248 and 249 of the human p53 gene. Oncogene. 1994;9:2277–2281
  37. Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int. J. Cancer. 1999;80:875–879
  38. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 1993;8:1109–1117
  39. Wang X, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA. 1994;91:2230–2234
  40. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 1995;9:41–47
  41. Lin Y, Nomura T, Yamashita T, Dorjsuren D, Tang H, Murakami S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res. 1997;57:5137–5142
  42. Madden CR, Finegold MJ, Slagle BL. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J. Virol. 2002;76:11770–11774
  43. Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004;205:173–180
  44. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur. J. Cancer Clin. Oncol. 1987;23:707–712
  45. Taback B, Hoon DS. Circulating nucleic acids in plasma and serum: past, present and future. Curr. Opin. Mol. Ther. 2004;6:273–278
  46. Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann. NY Acad. Sci. 2004;1022:76–80
  47. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, et al. Amount of DNA in plasma and cancer risk: a prospective study. Int. J. Cancer. 2004;111:746–749
  48. Wu T-L, Zhang D, Chia J-H, Tsao K-C, Sun C-F, Wu JT. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin. Chim. Acta. 2002;321:77–87
  49. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trépo C, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J. Natl. Cancer Inst. 2000;92:148–153
  50. Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 2001;61:33–35
  51. Szymanska K, Lesi OA, Kirk GD, Sam O, Taniere P, Scoazec JY, et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int. J. Cancer. 2004;110:374–379
  52. Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, Goedert JJ, et al. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol. Biomar. Prev. 2005;14:2956–2962
  53. Laken SJ, Jackson PE, Kinzler KW, Vogelstein B, Strickland PT, Groopman JD, et al. Genotyping by mass spectrometric analysis of short DNA fragments. Nat. Biotechnol. 1998;16:1352–1356
  54. Jackson PE, Kuang SY, Wang JB, Strickland PT, Munoz A, Kensler TW, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis. 2003;24:1657–1663
  55. Bártek J, Bártková J, Vojtĕsek B, Stasková Z, Lukás J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991;6:1699–1703
  56. Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur. J. Cancer. 2003;39:1828–1834
  57. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002;8:282–288
  58. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 2003;4:371–381
  59. Shi H, Lambert JM, Hautefeuille A, Bykov VJ, Wiman KG, Hainaut P, et al. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis. 2008;29:1428–1434
  60. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA. 2002;99:937–942
  61. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 1992;339:943–946
  62. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol. Biomar. Prev. 1994;3:3–10
  63. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer. 1996;67:620–625
  64. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, et al. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 1997;57:3471–3477

PII: S0304-3835(09)00169-4

doi: 10.1016/j.canlet.2009.02.057

Cancer Letters
Volume 286, Issue 1 , Pages 29-37 , 1 December 2009

Article Tools

* Image Usage & Resolution